학술논문

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Document Type
Artikel
Source
Blood advances. 4(9):1906-1915
Subject
Medicin och hälsovetenskap
Language
English
English
ISSN
2473-9537